Clinical Trials Logo
NCT number NCT03498456
Study type Interventional
Source CJ HealthCare Corporation
Contact Ah Rong Kim
Phone 82-2-6740-2441
Email ahrong.kim@cj.net
Status Not yet recruiting
Phase Phase 3
Start date April 30, 2018
Completion date February 6, 2020

Clinical Trial Summary

The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan after oral administration of the therapy for 7 days, twice daily in H. pylori positive patients.


Clinical Trial Description

This is a randomized, double blind, active controlled, multicenter, Phase 3 study to demonstrate the non-inferiority of tegoprazan triple therapy (TAC) to lansoprazole triple therapy (LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan in H. pylori positive patients after oral administration of therapy for 7 days, twice daily. After the treatment, UBT test will be conducted to confirm the Helicobacter pylori eradication.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Recruiting NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori N/A
Active, not recruiting NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT03134378 - 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Phase 4
Not yet recruiting NCT02894892 - Intragastric pH and Bismuth Effect for H. Pylori Eradication Phase 4
Not yet recruiting NCT02961296 - Helicobacter Pylori Antibiotic Susceptibility Testing of Korea N/A
Completed NCT02528721 - Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection Phase 3
Completed NCT02596620 - Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication N/A
Completed NCT02359435 - Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00736476 - Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults Phase 1
Completed NCT01730352 - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Phase 2/Phase 3
Completed NCT00867867 - Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries Phase 1
Recruiting NCT03193450 - Telephone-Based Re-education for Hp Eradication N/A
Recruiting NCT03317223 - A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients Phase 3
Recruiting NCT03299725 - Bismuth Based Quadruple Therapy 10 Days in Children Phase 4